Phase 2 Osteoarthritis Trial, Recruiting NCT06381791 Sponsor: The Methodist Hospital Research Institute Condition: Osteoarthritis
Back to Osteoarthritis

Phase 2 Osteoarthritis Trial, Recruiting

NCT06381791
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older
  • People who are scheduled to have rotator cuff repair surgery
  • People who will be receiving standard anaesthesia during their surgery
  • People who are capable of having children must be using effective contraception for one month before, during, and one month after treatment

Who may not be able to join:

  • People who are under 18 years of age
  • People who have had a previous revision shoulder replacement surgery
  • People with a history of liver disease or liver problems
  • People who are currently taking the medications valproate or clobazam
  • People who are currently taking certain medications that affect how the body processes drugs, known as moderate or strong CYP3A4 or CYP2C19 inhibitors (confirm with trial site)
  • People who are currently taking certain medications that affect how the body processes drugs, known as strong CYP3A4 or CYP2C19 inducers (confirm with trial site)
  • People who are currently taking narcotic (opioid) medications
  • People with a history of substance or alcohol abuse
  • People who are currently or have previously been under the care of a pain management specialist
  • People who have regularly used marijuana or cannabidiol products (other than topical/skin-applied forms) within the past 6 months
  • People who have a known allergy to cannabidiol
  • People who have a known allergy to sesame seeds
  • People who are pregnant (a urine pregnancy test will be carried out before surgery as part of standard care, and a negative result is required to participate)
  • People who are currently taking medications that are known to carry a risk of suicidal thoughts or behaviour
  • People who have a diagnosed psychiatric condition
  • People who have a diagnosed sleep disorder that is not currently being treated
  • People who are currently breastfeeding
  • People who are currently taking medications that slow or affect brain and nervous system activity, known as central nervous system (CNS) depressants
  • People who are currently taking other medications known to cause liver damage
  • People who are considered part of a vulnerable population (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Patrick McCulloch, MD, The Methodist Hospital Research Institute

Phone: 7134413930

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
The Methodist Hospital Research Institute
Registry
ClinicalTrials.gov
Start date
24 May 2024
Est. completion
30 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Primary - Pain Journal

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov